FilingSEC EDGAR8-K
Atossa Therapeutics Declares CVR Dividend for Potential Priority Review Voucher Proceeds
· SEC accepted
Stageclinical-stage
Filing content
The company declared a dividend of contingent value rights (CVRs) entitling shareholders to 25% of net proceeds from the potential future sale of an FDA priority review voucher, capped at $50 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…